Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
01 août 2023 09h00 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
17 juil. 2023 16h15 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
11 juil. 2023 08h30 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery...
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
16 juin 2023 09h05 HE
|
Clearmind Medicine Inc.
The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary...
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
09 juin 2023 09h30 HE
|
Clearmind Medicine Inc.
The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv, Israel / Vancouver, Canada, June 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:...
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
22 mai 2023 08h30 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 22, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery...
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
19 mai 2023 16h15 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on...
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
17 mai 2023 09h00 HE
|
Clearmind Medicine Inc.
The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv, Israel / Vancouver, Canada, May 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND),...
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
12 mai 2023 09h00 HE
|
Clearmind Medicine Inc.
IMCA medical center's ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) -- Clearmind...
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
09 mai 2023 16h15 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...